Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells
暂无分享,去创建一个
Y. Morine | M. Shimada | T. Ikemoto | Yu Saito | S. Yamada | C. Takasu | K. Tokuda | Katsuki Miyazaki | Luping Gao
[1] Yao Fu,et al. Cooperation between NRF2-mediated transcription and MDIG-dependent epigenetic modifications in arsenic-induced carcinogenesis and cancer stem cells. , 2021, Seminars in cancer biology.
[2] M. Kwak,et al. The multifaceted role of NRF2 in cancer progression and cancer stem cells maintenance , 2021, Archives of Pharmacal Research.
[3] J. Yun,et al. NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma , 2020, Cancer Letters.
[4] Xiaolu Yang,et al. TRIM25 promotes the cell survival and growth of hepatocellular carcinoma through targeting Keap1-Nrf2 pathway , 2020, Nature Communications.
[5] A. I. Rojo,et al. Transcription factor NRF2 uses the Hippo pathway effector TAZ to induce tumorigenesis in glioblastomas , 2020, Redox biology.
[6] N. Samadi,et al. The Role of Nrf2 signaling in cancer stem cells: from stemness and self-renewal to tumorigenesis and chemoresistance. , 2019, Life sciences.
[7] Jia Hu,et al. Pxr- and Nrf2- mediated induction of ABC transporters by heavy metal ions in zebrafish embryos. , 2019, Environmental pollution.
[8] I. Ng,et al. Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC , 2019, Nature Communications.
[9] M. Parola,et al. Of FACT complex and oxidative stress response: a KEAP1/NRF2-dependent novel mechanism sustaining hepatocellular carcinoma progression , 2019, Gut.
[10] Ya Cao,et al. Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target , 2019, BMC Cancer.
[11] Y. Morine,et al. Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction , 2018, Cell Communication and Signaling.
[12] In-geun Ryoo,et al. High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenase (ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling , 2018, Cell Death & Disease.
[13] A. Yu,et al. Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells , 2018, Drug Metabolism and Disposition.
[14] A. Bosserhoff,et al. Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance , 2017, Gut.
[15] G. Cassinelli,et al. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents. , 2017, European journal of medicinal chemistry.
[16] Cheng Chen,et al. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma. , 2017, Cancer letters.
[17] Y. Seong,et al. Silencing of NRF2 Reduces the Expression of ALDH1A1 and ALDH3A1 and Sensitizes to 5-FU in Pancreatic Cancer Cells , 2017, Antioxidants.
[18] L. Qu,et al. Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma , 2017, Oncogene.
[19] B. Zhai,et al. Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells , 2017, Molecular oncology.
[20] Yang Zhang,et al. NRBP2 Overexpression Increases the Chemosensitivity of Hepatocellular Carcinoma Cells via Akt Signaling. , 2016, Cancer research.
[21] P. Pascuzzi,et al. EpCAM-regulated intramembrane proteolysis induces a cancer stem cell-like gene signature in hepatitis B virus-infected hepatocytes. , 2016, Journal of hepatology.
[22] Brandon Da Silva,et al. NRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer , 2016, Cell.
[23] W. El-Deiry,et al. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC) , 2016, Clinical Cancer Research.
[24] J. Wang,et al. Lysine-specific demethylase 1 promotes the stemness and chemoresistance of Lgr5+ liver cancer initiating cells by suppressing negative regulators of β-catenin signaling , 2015, Oncogene.
[25] Jessica Zucman-Rossi,et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.
[26] Takafumi Suzuki,et al. Toward clinical application of the Keap1-Nrf2 pathway. , 2013, Trends in pharmacological sciences.
[27] M. McMahon,et al. Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway. , 2010, Antioxidants & redox signaling.
[28] J. Llovet,et al. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. , 2010, Annual review of medicine.
[29] X. Wang,et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.
[30] S. Boyault,et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.
[31] S. Wilhelm,et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. , 2006, Cancer research.
[32] Y. Kan,et al. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[33] A. Yu,et al. Bioengineered NRF 2-siRNA is effective to interfere with NRF 2 pathways and improve chemosensitivity of human cancer cells , 2017 .
[34] C. Gonçalves,et al. [Hepatocellular carcinoma]. , 1988, Arquivos de gastroenterologia.